东亚药业：首张制剂批文落地，原料药制剂一体化加速兑现

Core Viewpoint - East Asia Pharmaceutical has received approval for Levofloxacin tablets, marking a significant milestone in its integrated development strategy of active pharmaceutical ingredients (APIs) and formulations [1][2] Group 1: Product Approval and Market Impact - The approval of Levofloxacin tablets is the first formulation product approved under the company's strategy, indicating a major breakthrough in its integrated development approach [1] - Levofloxacin, a broad-spectrum antibiotic, is expected to generate approximately 435 million yuan in sales in 2024, highlighting its market potential [1] - The approval is expected to enhance the company's product line, improve competitiveness, and contribute to sustainable and healthy growth [2] Group 2: Strategic Development and Investment - The company has raised nearly 700 million yuan through convertible bonds, with 350 million yuan allocated for the construction of a formulation factory, which will produce 17 products including Levofloxacin tablets [2] - By the end of 2024, the company has received acceptance for 8 formulation applications involving 6 products, with over 10 additional formulations planned for submission [2] - The integrated strategy aims to solidify the company's market position in the API sector and drive its vision of becoming a leading domestic and international pharmaceutical enterprise [1][2]